ISSN 1677-5449 printed version portuguese
ISSN 1677-7301 online version

INSTRUCTIONS TO AUTHORS

 

Scope and policy

J Vasc Bras is a peer-reviewed quarterly publication of the Brazilian Society of Angiology and Vascular Surgery (Sociedade Brasileira de Angiologia e de Cirurgia Vascular - SBACV). It is directed to vascular surgeons and clinicians and to professionals of related fields, and accepts submissions in Portuguese, English and Spanish. The mission of the Journal is to select and disseminate high-quality scientific contents concerning original research, novel surgical and diagnostic techniques, and clinical observations in the field of vascular surgery, angiology, and endovascular surgery.

The J Vasc Bras Instructions to Authors follow the recommendations found in the latest version of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals of 2009. The complete document is available at www.icmje.org.

GENERAL INFORMATION

Manuscripts that are not in accordance with the following instructions will be returned to the authors for correction before review by the Editorial Board.

1. Manuscripts submitted for publication should not have been published or submitted to other journals in part or in whole.

2. Materials published in J Vasc Bras become the property of the Journal and of SBACV and may not be reproduced elsewhere in part or in whole without written permission from J Vasc Bras and from SBACV and without citation of the original source. All submitted articles should be accompanied by a Copyright Transfer Agreement (Intellectual Property), described below.

3. Articles including previously published figures should cite the original source in the corresponding legends. Written permission must be obtained from the copyright holder (publishing house or journal).

4. We recommend that authors keep a copy of the materials submitted to J Vasc Bras, since they will not be returned to the authors.

5. J Vasc Bras will not consider editorials which were not invited by the Editor-in-Chief.

6. Manuscript receipt will be acknowledged via an automatic e-mail message generated by the submission system (http://mc04.manuscriptcentral.com/jvb-scielo). If the paper is in accordance with the Instructions to Authors and with the editorial policies of the Journal, it will be reviewed by two referees assigned by the Editor-in-Chief. Authors and reviewers will remain anonymous throughout the review process. Within 60 days, the authors are informed of either acceptance, rejection, or the need for revisions in the article, as requested by the Editorial Board. A decision letter and reviewers’ comments will be e-mailed to the authors. Authors will be requested to return a revised version of the manuscript within 1 month and to provide a letter detailing their responses to the reviewers’ comments. Revised manuscripts should clearly indicate changes made to the text, using red font preferably. Revised manuscripts will be sent back to reviewers for reassessment. At this time, a decision will be taken for the acceptance, rejection, or the need for additional revisions.

Below, we disclose the Assessment Questionnaire to the general public, so as to ensure total transparency of the editorial process.

- Does the manuscript contain new and significant information to justify publication?
- Does the Abstract (Summary) clearly and accurately describe the content of the article?
- Is the problem significant and concisely stated?
- Are the methods described comprehensively?
- Are the interpretations and conclusions justified by the results?
- Is adequate reference made to other work in the field?
- Is the language acceptable?
- Please rate the priority for publishing this article (1 is the highest priority, 10 is the lowest priority).
- Manuscript Structure: Is the length of the article, number of tables and figures adequate? Too short/few? Too long/many?
- Please state any conflict(s) of interest that you have in relation to the review of this paper (state "none" if this is not applicable).
- Please rate the article for Interest, Quality, Originality, and Overall, choosing between Excellent, Good, Average, Below Average, or Poor.
- Confirm that the study was approved by an Ethics Committee.
- Recommendation: Accept, Minor Revision, Major Revision, Reject & Resubmit, or Reject.
- Would you be willing to review a revision of this manuscript?

7. A maximum of eight authors per manuscript is allowed. Studies with more than eight authors should include a statement providing a reason for the inclusion of each author. In cases of collective (corporate) authorship, the group should identify the individuals taking direct responsibility for the manuscript. According to the Uniform Requirements edited by the International Committee of Medical Journal Editors (ICMJE), "authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3" (http://www.icmje.org/ethical_1author.html). Inclusion of authors’ names whose contributions do not fulfill these criteria is not warranted.  Also, authors’ names will be published in the exact order in which they appear in the title page of the original submission. The order of authors cannot be changed, and new authors cannot be included, after acceptance or during the production stage, unless a justification for such change, in writing, signed by all authors, is timely presented to the production team. A supplementary statement describing the specific contributions of each author to the study should be provided for each manuscript, as described in detail below.

8. Authors must disclose, by means of a supplementary statement or along with each author’s name, any conflicts of interest that might bias, or in any way impact the integrity of, the submitted manuscript. Some examples include publications, public statements related to the subject of the manuscript, participation in an industry advisory committee, or other activities related to industry sources. Authors should use the list below as a criterion for the statement of potential conflicts of interest:

- to participate in clinical and/or experimental trials supported by a commercial entity;
- to participate in speaking activities related to industry sources;
- to be a consultant to or director of a commercial entity;
- to participate in an industry advisory committee receiving money for completion of research;
- to receive grant monies from a commercial entity;
- to be a shareholder of a commercial entity;
- to have a family relationship with owners/directors of a commercial entity having an interest in the subject of the manuscript; 
- to produce scientific reports in journals supported by a commercial entity; 
- to have any financial relationship with people and institutions that might affect the integrity of the manuscript (e.g., being an employee, consultant or shareholder of a commercial entity, receiving honoraria, providing expert testimony, holding patent rights or having a patent application pending, receiving grants or other types of financial support).

9. Authors will be informed of the acceptance of their articles via a decision letter sent by our submission system. This message is the official acceptance document issued by the Journal; no other documents will be issued with the same purpose. Once accepted, manuscripts will enter the production process (press) of J Vasc Bras and will be published in a future issue, as decided by the Editor-in-Chief. Changes to the text or to author names will not be allowed at this stage. The editorial office of the Journal will not provide information on the exact date of publication or on the issue in which the article will be published, since the contents of each issue are decided exclusively by the Editor-in-Chief.

10. A statement concerning approval of the study by the institutional research ethics committee (or equivalent) should be included with the manuscript. International authors should state that the manuscript is in accordance with the Helsinki Declaration and with local ethical guidelines. Informed consent should be obtained where appropriate, and this should be clearly indicated in the article. The authors should keep copies of informed consent forms and other documents required by the Ethics Committee at the institution in which the work was carried out. Animal experiments should conform with guidelines applicable to this type of study.

11. J Vasc Bras supports the policy of registration of clinical trials by the World Health Organization (WHO) and the ICMJE, recognizing the importance of such initiatives for registration and public access to information on clinical trials. According to this recommendation, clinical trials should be registered in one of the Clinical Trials Registries recommended by the WHO and the ICMJE. Addresses are available at the ICMJE website (e.g., www.actr.org.auwww.clinicaltrials.govwww.ISRCTN.org, www.umin.ac.jp/ctr/index/htm, and www.trialregister.nl). In Brazil, clinical trials can be registered on www.ensaiosclinicos.gov.br. The clinical trial registration number should appear below the abstract. All manuscripts resulting from randomized clinical trials should have a clinical trial registration number.

12. Before publication, page proofs (PDF file) are sent to the corresponding author for approval. Authors should download Acrobat Reader (http://get.adobe.com/br/reader/, download free of charge) to read the PDF file. Proof corrections should be limited to typesetting errors. No substantial changes will be accepted at this stage. Corrected proofs should be returned within 48 hours of receipt via e-mail (jvasc@infocentral.com.br). Once the production process of the PDF files is completed, the article will be sent to publication ahead of print at SciELO (http://www.scielo.br/).

 

Manuscripts' form and presentation

TYPES OF ARTICLES

J. Vasc. Bras. publishes:

1. Complete original articles reporting the results of prospective, experimental, or retrospective studies, as well as articles awarded in congresses. These articles will be given priority for publication. They should be composed of: title page (submitted as a separate file), structured abstract (including the following sections: Background, Objectives, Methods, Results, and Conclusions, with no more than 250 words) and keywords in English, structured abstract and keywords in Portuguese (if possible), text (Introduction, Methods, Results, Discussion or equivalent), acknowledgements (if applicable), references, tables (if applicable), figure legends (if applicable) and figures (if applicable). Original articles should not exceed 3,000 words (not including title page, abstract, tables, figures, and references) and 40 references.

2. Presentation of novel diagnostic, surgical, and clinical treatments, as long as there are no clear or disguised commercial purposes or associations with pharmaceutical or medical device companies. They should be composed of: title page (submitted as a separate file), unstructured abstract (with no more than 150 words) and keywords in English, unstructured abstract and keywords in Portuguese (if possible), text, references, tables (if applicable), figure legends (if applicable) and figures (if applicable). Innovations should have a with no more than 3,000 words and 30 references.

3. Brief communications, i.e., initial or preliminary and partial results of clinical or surgical studies under development, or of the application of an innovative technique. They should be composed of: title page (submitted as a separate file), unstructured abstract (with no more than 150 words) and keywords in English, unstructured abstract and keywords in Portuguese (if possible), text, references, tables (if applicable), figure legends (if applicable) and figures (if applicable). Brief communications should have a maximum length of 1,500 words and 25 references.

4. Review articles, including meta-analyses and editorial comments. They should be composed of: title page (submitted as a separate file), unstructured abstract (with no more than 150 words) and keywords in English, unstructured abstract and keywords in Portuguese (if possible), text, references, tables (if applicable), figure legends (if applicable) and figures (if applicable). Review articles should be up to 5,000 words long, with a with no more than 100 references.

5. Well-documented case reports of great interest in terms of clinical and laboratory findings. J Vasc Bras will only accept case reports of a rare entity, pioneer or innovative treatment, or unexpected results. They should be composed of: title page (submitted as a separate file), unstructured abstract (with no more than 150 words) and keywords in English, unstructured abstract and keywords in Portuguese (if possible), text (Introduction, Case description and Discussion or equivalent), references, figure legends (if applicable) and figures (if applicable). Case reports should have a with no more than 1,500 words and 25 references.

6. J Vasc Bras publishes Therapeutic challenge, divided into four parts, as follows: 1) Introduction; 2) Part I - Clinical situation, describing the case or situation, including images and/or examinations performed, followed by pertinent questions regarding additional diagnostic means and/or therapeutic conducts; 3) Part II - What was done?, describing the conduct of choice, including procedures (surgical or clinical), additional examinations, progress of follow-up (if applicable), etc.; 4) Discussion, including a final paragraph with the conclusions of the study. They should be composed of: title page (submitted as a separate file), abstract and keywords, in both Portuguese and English, if possible, text, references, tables, figure legends (if applicable), and figures (if applicable). Therapeutic challenges should not exceed 1,500 words and 25 references.

7. Abstracts of dissertations presented and approved within 12 months prior to the submission date. They should be composed of: dissertation title, full name of the author, advisor, and members of the dissertation committee, date and service/department/program where the dissertation was developed and presented, abstract (main text) and keywords. Dissertation abstracts should be structured and should have no more than 350 words.

8. Letters to the Editor concerning editorial subject or published articles. They should be composed of: title, name of the author (submitted separately), identification of the article commented, references (if applicable). Letters should have no more than 350 words.

9. Special issues, such as annals of congresses, guidelines, collections of works presented at conferences sponsored by SBACV, and supplements focusing on specific topics may be organized upon request to the Editor-in-Chief.

MANUSCRIPT PREPARATION

All manuscripts should be typed double-spaced and left aligned, including all sections: title page, text, references, tables, and figure legends.

Manuscripts should be typed as a Microsoft Word© document, font Times New Roman, size 12. Do not highlight any parts of the text using underline or bold. All pages should be numbered. A title page, submitted in a separate file, should contain the following items:

1) title of the manuscript in Portuguese;
2) title of the manuscript in English;
3) short title (do not use acronyms), in the same language of the manuscript (maximum of 50 characters including spaces);
4) full names of all authors;
5) author affiliations (please inform: Institution - ACRONYM, Department, Municipality, State, Country);
6) correspondence information (please inform: name of the corresponding author/ Full postal address/ Zip code – Municipality (State), Telephone, Country/ E-mail);
7) author information (please inform: author initials followed by main position/occupation (e.g.: "GBPB holds a MSc degree in Surgery from Universidade Federal de São Paulo (USP)"); 
8) institution where the study was carried out (e.g.: "This study was carried out at...").

Full names of the authors and co-authors, their affiliations and details on the corresponding author (name, address, telephone number, fax, and e-mail)  should also be informed in the specific fields of the system (metadata) and removed from the manuscript document to assure blind peer review. Names of the institutions in which the work was carried out or to which the authors are affiliated, as well as congresses where the study was presented, should not be mentioned in the text either. Such information can be provided separately and submitted as a supplementary file. In addition, authors should inform the specific contributions of each author to the study, following the model presented below, including initials of the authors involved in each of the tasks listed:

Conception and design:
Analysis and interpretation:
Data collection:
Writing the article:
Critical revision of the article:
Final approval of the article*:
Statistical analysis:
Overall responsibility:
Obtained funding:
* All authors should have read and approved of the final version of the article submitted to J Vasc Bras.

Do not use capital letters to write names (e.g., SMITH) within the text or in the references. Do not use periods after the letters in acronyms or abbreviations (AAA rather than A.A.A.). The spelled-out forms of abbreviations/acronyms should be given at first mention, followed by the abbreviation/acronym in parenthesis; thereafter, only the abbreviation/acronym should be used. Abbreviations used in tables and figures should be explained in footnotes, even when they have been previously defined in the text. Names of commercial products should be followed by the trademark symbol (®); the following information should also be mentioned: name of manufacturer, city and country where the product was manufactured.

The use of abbreviations and symbols should be avoided in the abstract. References should not be cited in the abstract. 
At least three keywords should be listed below the abstract. Keywords should be in accordance with the Medical Subject Headings (http://www.nlm.nih.gov/mesh/meshhome.html) elaborated by the National Library of Medicine. 

Tables

Tables (each table typed on a separate sheet) should be cited in the text and numbered using Arabic numbers in the order in which they appear in the text, with an explanatory title and notes if applicable. Tables should be inserted in the main file, following the references. Use only horizontal borders before and after the column headers and at the foot of the table. Do not use vertical borders.

Tables should not duplicate information previously described in the text. In addition, readers should be able to understand data provided in tables without reference to the text. Abbreviations used in tables should be explained in footnotes.

Figures

All figures should be cited in the text (always called "Figure," not "Graph" or "Image") and numbered using Arabic numbers in the order in which they appear in the text, with an explanatory legend. All legends should be listed on the same page at the end of the article. Color figures are accepted for online publication, but are printed in black and white; therefore, all figures should be intelligible in black and white.

Figures should be submitted as electronic files (only digital images and photographs will be accepted), in separate files, using extensions .jpg, .gif or .tif, with a resolution of 300 dpi or higher to enable good-quality reproduction. Figures should be submitted electronically. If this is not possible, illustrations should be sent via regular mail. Scanned photographs will not be accepted; paper photographs should be submitted via regular mail. 

Photographs should not allow patient identification. Graphs should be bidimensional.

If the resolution of the figure submitted electronically is not considered adequate for printing, the Journal may contact the authors and request the submission of a high-resolution version. Identify all photographs sent via regular mail with a label on the back of the figure, indicating first author’s name and top of the figure (with an arrow).

Do not send original X-rays, materials produced in heat-sensitive paper, or any other medical records. Instead, submit two sets of good-quality copies of these materials to enable reproduction.

Figures previously published and included in submitted articles should cite the original source in the legend and must be accompanied by written permission from the copyright holder (publishing house or journal). The authors should keep a copy of the permission letter(s).

Figures should not duplicate information previously described in the text. In addition, readers should be able to understand data provided in figures without reference to the text. Abbreviations used in figures should be explained in the legend.

Acknowledgments

In this section, acknowledge the work of people who contributed intellectually to the manuscript, but whose contribution does not justify authorship. Also acknowledge any material support received.

References

All the authors and works cited in the text should be included in the reference list and vice-versa. References should be numbered consecutively in the order in which they appear in the text (not in alphabetical order), identified by superscript numbers (not by numbers in parentheses). References should follow the order in which they appear in the text. Avoid citing too many references. Select the most relevant references, and focus on the most recent works (past 5 years).
If possible and relevant, cite Brazilian and Latin American authors via the following sources: LILACS (www.bireme.com.br), SciELO (www.scielo.br) and J Vasc Bras (www.cielo.br/jvb and www.jvascbr.com.br).

Avoid citations that are not easily available to readers, such as abstracts presented at conferences or restricted publications. Do not use •personal communications• as references. Papers that have been accepted for publication but now yet published may be cited followed by the expression •in press.• For citation of other works by the authors, select only original journal articles which are related to the topic under discussion (do not include book chapters or review articles). The authors are responsible for the accuracy of the references and should follow the style shown in the examples below.

Journal articles:

1. Harvey J, Dardik H, Impeduglia T, Woo D, Debernardis F. Endovascular management of hepatic artery pseudoaneurysm hemorrhage complicating pancreaticoduodenectomy. J Vasc Surg. 2006;43:613-7.

2. The UK Small Aneurysm Trial Participants. Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. Lancet. 1998;352:1649-55.

3. Hull RD, Pineo GF, Stein PD, et al. Extended out-of-hospital low molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med. 2001;135:858-69.

If there are more than six authors, cite the first three followed by •et al.• Cite all authors if there are six or fewer. Please note that a period should be inserted after the abbreviated name of the journal.

Book chapters:

4. Rutherford RB. Initial patient evaluation: the vascular consultation. In: Rutherford RB, editor. Vascular surgery. Philadelphia: WB Saunders; 2000. p. 1-12.

Journal article on the Internet:

5. Abood S. Quality improvement initiative in nursing homes: the ANA acts in an advisory role. Am J Nurs [serial on the internet]. 2002 Jun [cited 2002 Aug 12];102(6):[approximately 3 p.]. http://www.nursingworld.org/AJN/2002/june/Wawatch.htm

Journal article published on the Internet:

6. Wantland DJ, Portillo CJ, Holzemer WL, Slaughter R, McGhee EM. The effectiveness of web-based vs. non-web-based interventions: a meta-analysis of behavioral change outcomes. J Med Internet Res. 20004;6(4):e40. http://www.jmir.org/2004/4/e40/. Accessed Nov 29 2004. 29/11/2004.

Homepage/Web Site:

7. OncoLink [site on the Internet]. Philadelphia: University of Pennsylvania; c1994-2006. [updated 2004 Sep 24; cited 2006 Mar 14].http://cancer.med.upenn.edu/.

Software:

8. Smallwaters Corporation. Analysis of moment structures: AMOS [software]. Version 5.0.1. Chicago: Smallwaters; 2003.

AUTHOR CHECKLIST

• Title (in English and Portuguese, if possible).
• Short title (up to 50 characters with spaces).
• Full names of all authors.
• Name of the institution in which the work was carried out or to which the authors are affiliated.
• Conflict of interests declaration according to the checklist presented in General Information, item 8, of this Instructions to Authors (e.g., grants, devices or drugs received as financial support, or other relationships that may influence the published results).
• Studies resulting from randomized clinical trials should be accompanied by a statement of registration in one of the Clinical Trial Registries recommended by the WHO and the ICMJE. This category includes any prospective study (cohort, case series, randomized clinical trial, etc.) approved by the ethics committee, involving patients or groups of patients, in which authors assess and compare treatments, procedures, diagnostic techniques, etc.
• Name, full mailing address, phone, fax and e-mail of corresponding author.
• Up to 250-word structured abstract for original articles or up to 150-word unstructured abstract for case reports and review articles.
• At least three keywords (indexed in DeCS, http://decs.bvs.br).
• All pages are numbered.
• All figures and tables are cited and numbered in the order in which they appear in the text.
• Figures and tables do not repeat data already described in the text.
• Figures do now allow identification of the patient.
• All references are cited in the text and are numbered in the order in which they appear in the text, with superscript numbers.
• References are adequately formatted (according to examples).
• There are citations of Brazilian and Latin American authors (whenever relevant).
• The authors have copies of informed consent forms and other documents required by the Ethics Committee at the institution in which the work was carried out.
• The authors have written permission for the use of previously published figures.
• If the article is being submitted via regular mail, one hard copy and a diskette are being submitted.

 

The sending of manuscripts

All manuscripts should be submitted via the ScholarOne/SciELO submission system, available at http://mc04.manuscriptcentral.com/jvb-scielo. Register your login data (login and password) and follow the steps in order to submit your manuscript.

If you have any doubts, please contact the editorial office via e mail denise@scientific.com.br or at the telephone number +55 (51) 9829.1725.

Jornal Vascular Brasileiro
Editorial Office
Rua Maranguape, 72, térreo
CEP 90690-380 - Porto Alegre, RS - Brazil
Tel.: +55 (51) 9829.1725 (Denise Arend)
E-mail: denise@scientific.com.br

Copyright Transfer Agreement (Intellectual Property)

Dear Editor,
By the present, we, the undersigned authors, submit this manuscript entitled (title of study), hereby written by us and presented as an article in the category (manuscript type) to the Editorial Board of the J Vasc Bras (Jornal Vascular Brasileiro) for publication. In accordance with the regulation contained in the "Authors Instruction", we inform that:
a) the referred study was performed at (name of institution);
b) the protocol was approved by the institution Ethics Committee;
c) informed consent was obtained for studies that involved humans;
d) we irrevocably concede to the Brazilian Society of Angiology and Vascular Surgery (Sociedade Brasileira de Angiologia e de Cirurgia Vascular - SBACV), in the case of acceptance for publication, copyright of the study that we are hereby submitting, recognizing that all the contents of the journal, except where otherwise noted, are licensed under a Creative Commons License. Total or partial reproduction is forbidden without prior and necessary authorization request in writing and obtained jointly by the SBACV;
e) we have kept a copy of the present submitted manuscript; and
f) the study was supported financially by (names of the institutions that gave support for the study).

With respect to influence or bias the results of this study (conflicts of interest) – we acknowledge the following conflicts of interest (explain, if any, relationships that involve, professional, financial, or direct or indirect beneficiary conflicts of interest, or explicitly declare the inexistence of such associations).
To facilitate correspondence exchange, the following author was designated as correspondence author. Name of chosen author, followed by the name of the institution, complete postal address, telephone number and, if possible, eletonic address.
We presently submit and await manifestation of notification.

Sincerely,
(Date and location, followed by the signatures and respective full names)

 

[Home] [About this journal] [Editorial board] [Subscription]


Creative Commons License All the content of the journal, except where otherwise noted, is licensed under a Creative Commons License

Rua Estela, 515, bloco E, conj. 21, Vila Mariana
CEP04011-002 - São Paulo, SP
Tel.: (11) 5084.3482 / 5084.2853


secretaria@sbacv.org.br